'Landmark' advance as malaria vaccine first to hit WHO goal
In a clinical trial in Burkina Faso, the Matrix-M vaccine -- developed by the University of Oxford's Jenner Institute -- was found to be 77 percent effective after 450 infants inoculated in 2019 were followed up for a year, the Oxford researchers said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Burkina Faso Health | Clinical Trials | Malaria | Malaria Vaccine | Oxford University | Pharmaceuticals | Vaccines